Drug intelligence / Profile preview

VB-08

Development stage: Preclinical
Lead developer: Vincere Biosciences
Modality: Small Molecules

Overview

VB-08 is a small molecule inhibitor of Ubiquitin-specific protease 30 (USP30) developed by Vincere Biosci. Its mechanism of action involves enhancing mitophagy, the cellular process responsible for clearing damaged mitochondria. The drug is currently under investigation for its therapeutic potential in treating Acute Kidney Injury (AKI), preventing Chronic Kidney Disease (CKD) progression, and addressing Parkinson's Disease (PD).

Targets

USP30 (Ubiquitin-specific peptidase 30)

Beyond the preview

Go deeper on VB-08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB-08.

Explore the full profile